Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
4.040
-0.150 (-3.58%)
At close: Jun 18, 2026, 4:00 PM EDT
4.170
+0.130 (3.22%)
After-hours: Jun 18, 2026, 5:42 PM EDT
Femasys Revenue
Femasys had revenue of $424.89K in the quarter ending March 31, 2026, with 24.50% growth. This brings the company's revenue in the last twelve months to $2.38M, up 39.88% year-over-year. In the year 2025, Femasys had annual revenue of $2.29M with 40.77% growth.
Revenue (ttm)
$2.38M
Revenue Growth
+39.88%
P/S Ratio
5.13
Revenue / Employee
$44,017
Employees
54
Market Cap
12.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.29M | 664.20K | 40.77% |
| Dec 31, 2024 | 1.63M | 557.14K | 51.97% |
| Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
| Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
| Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
| Dec 31, 2020 | 1.04M | 108.86K | 11.72% |
| Dec 31, 2019 | 929.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 85.53M |
| Retractable Technologies | 37.15M |
| Bionano Genomics | 28.74M |
| Jin Medical International | 20.69M |
| Nephros | 19.12M |
| NEXGEL | 11.27M |
| Milestone Scientific | 8.90M |
| Lucyd | 2.98M |
FEMY News
- 14 days ago - Femasys Inc trading halted, news pending - TheFly
- 5 weeks ago - Femasys announces CE Mark approval for FemHSG Catheter - TheFly
- 5 weeks ago - Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter - GlobeNewsWire
- 5 weeks ago - Femasys Slides: Corporate presentation - Filings
- 6 weeks ago - Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Femasys Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Femasys Earnings release: Q1 2026 - Filings
- 6 weeks ago - Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete - GlobeNewsWire